investigate the effectiveness and safety of adding vitamin K2 at a dose of 45 mg/day for 12 weeks to conventional therapy for paediatric patients with moderate to severe atopic dermatitis according to SCORAD score

This was a multicentre, prospective, blind randomized. patients are randomized to either receive their conventional therapy alone or by adding vitamin k2 for 12 weeks. The primary outcome was to evaluate the impact of vitamin K2 on the severity of atopic dermatitis, as assessed by the SCORAD score at 12 weeks compared to baseline.

Inclusion Criteria:

• patients aged 6-12 years
• moderate to severe AD according to SCORAD score

Exclusion Criteria:

• other cutaneous allergic diseases (urticaria, angioedema, anaphylaxis, contact dermatitis).
• primary immunodeficiency (PID) with cutaneous allergic manifestations.